FDA Requests Additional Trial On Pain Drug

First App Launched to Identify Drug Shortages
First App Launched to Identify Drug Shortages
AcelRx officials noted that the FDA is asking for the additional clinical study to assess the risk of inadvertent dispensing and overall risk of dispensing failures.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, provided an update on the timing and potential content of the resubmission of the New Drug Application or NDA for Zalviso.

READ FULL ARTICLE Curated publisher From RTT News